BD unveils $1.2 billion investment in pre-fillable syringe manufacturing
World’s largest syringe maker gears up for increased demand across all product classes amid expected COVID-19 vaccine roll out
Becton Dickinson has announced plans to invest $1.2 billion over the next four years in expanding and upgrading its global pre-fillable syringe manufacturing capacity and technology and advanced drug delivery systems over the next four years, including a new production facility in Europe.
The announcement comes at a time when global demand for syringes is projected to soar with COVID-19 vaccination programmes expected to start taking off in earnest in 2021.
The company said the investment will fund capacity expansion, new product innovations, manufacturing technology enhancements and business continuity improvements across its existing network.
The six current manufacturing facilities for BD Pharmaceutical Systems that are lined up for the cash injection are in Columbus, Nebraska; Cuautitlán, Mexico; Fukushima, Japan; Le Pont-de-Claix, France; Swindon, UK; and Tatabánya, Hungary.
“This new commitment will invest in additional upgrades at all of our Pharmaceutical Systems manufacturing facilities and across multiple product categories,” said Eric Borin, worldwide president of BD Pharmaceutical Systems.
He added that the move would provide BD with the needed surge capacity for increased pre-fillable syringe demand during times of pandemic response or periods of significant growth of new injectable drugs and vaccines.
BD, the world’s largest syringe manufacturer, is regarded as the pioneer of pre-fillable technology. The new manufacturing facility in Europe is expected to be operational by the end of 2023.
Related News
-
News Accepting novel excipients for innovative drug development
With the rapid development and manufacturing of new drugs and therapeutics being pushed through the pipeline, excipient manufacturers are navigating a challenging landscape to meet the demand for new and novel excipients. -
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News Connect to Frankfurt - Five reasons to tune in
Get a jump-start on your CPHI Frankfurt experience with exclusive access to our online event platform. -
News WHO calls on public for ideas to rename monkeypox
‘Poxy McPoxface’, ‘TRUMP-22’, and ‘Mpox’ are just some of the suggestions submitted by the public -
News Chinese market represents ‘single greatest generational opportunity’ for Pharma
China’s pharmaceutical industry is changing from formerly generics-focused into one that emphasizes innovation, spurred by shifting government policy and an aging population. -
News Monkeypox Update: Vaccine shortage, sewage surveillance and global testing
As concern over the monkeypox outbreak continues to rise, we take a look at major developments from the first week of August. -
News mRNA production partnership to scale-up COVID-19 vaccine development
GreenLight Biosciences and Samsung Biologics announce mRNA production partnership to scale mRNA vaccine production to a commercial level with Samsung's expanded mRNA drug substance manufacturing site. -
News The Data Revolution: How Real-World Evidence is Changing Pharma
A look at the companies extracting valuable insights from health data to accelerate clinical development and support regulatory decision making.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance